Facility ID#: Med Admin#: Healthcare Worker Demographics *HCW ID#: *HCW Name, Last:First:Middle: *Gender:  F  M  Other *Date of Birth:// *Work Location:*Occupation:

Slides:



Advertisements
Similar presentations
Waqas Tahir GPST2. Overview Introduction Introduction Mechanism of action Mechanism of action Therapeutic uses Therapeutic uses Pharmacokinetics Pharmacokinetics.
Advertisements

Important Highlights for the Completion of DD Form 2792 Family Member Medical Summary MCCS Camp Allen EFMP Office DD Form 2792 must be completed for all.
Facility ID:________________Event#_________________________ *Patient ID:_____________________ Social Security#: __ __ __ - __ __ - __ __ __ __ Secondary.
Introduction to the National Healthcare Safety Network (NHSN) Richard Rodriguez, MPH Connecticut Department of Public Health 4/9/2014 Thank you to CDC.
Content Management Portal PRA Disclosure Statement According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection.
Highlights for the Completion of DD Form 2792 “Family Member Medical Summary” NAVAL MEDICAL CENTER PORTSMOUTH EFMP COORDINATOR OFFICE DD Form 2792 must.
1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.
Learning objectives:- 1. Introduction. 2. Define health record. 3. Explain types of health record. 4. Mention purposes of health record. 5. List general.
Content Management Portal PRA Disclosure Statement According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection.
Health Insurance Portability and Accountability Act (HIPAA)
Assessing the Impact of a Toll-Free Number for Reporting Side Effects in Direct-to-Consumer Television Ads: Proposed Study Design Kathryn J. Aikin, Ph.D.
DATA PROTECTION AND PATIENT CONFIDENTIALITY IN RESEARCH Nic Drew Data Protection Manager University Hospital of Wales   
1 One Year Post-Exclusivity Adverse Event Review for Tamiflu® (oseltamivir) Pediatric Advisory Committee Meeting November 18, 2005 Melissa M. Truffa, R.Ph.
Facility ID#: *HCW ID#:Social Security #: Secondary ID#: HCW Name, Last: First: Middle: Street Address: City:State:Zip Code: Home Phone: ( ) Address:
EMPLOYEE INFLUENZA VACCINATON. Influenza Vaccination (Your institution) is committed to keep both its employees and patients safe (Your institution) recognizes.
C#OMPANY LOGO OMB Control Number HealthCare.gov Data Collection August 31, 2010 Training.
Prepared by the Division of Emergency Medical Services Refresher Course Medical Incident Report Form Education Module for 2009 Prepared by the Division.
Regulation of Promotion of Prescription Drugs Thomas W. Abrams, R.Ph., MBA Division of Drug Marketing, Advertising, and Communications Food and Drug Administration.
SPM 100 Clinical Skills Lab 1 Standard Precautions Sterile Technique Daryl P. Lofaso, M.Ed, RRT.
A Patient taking overdose of sleeping pills By Dr WL Yip, AED, QMH.
SPM 200 Clinical Skills Lab 4 Local Anesthesia / Digital Block Daryl P. Lofaso, M.Ed, RRT.
Facility ID: Vaccination #: Healthcare Worker Demographics *HCW ID#: HCW Name, Last:First:Middle: *Gender:  F  M *Date of Birth: *Work Location: *Occupation:
Active Surveillance for Adverse Drug Events Dan Budnitz, MD, MPH National Center for Injury Prevention & Control November 9, 2004 Collaborative Effort.
2003 Prehospital Patient Care Protocols
CLINICAL PHARMACOKINETICS OF LIDOCAINE
Health Insurance portability and Accountability Act (HIPAA)‏
Mette Krag, MD, coordinating investigator
HIPAA and Human Subjects Research IRB Member CE May 2014 Slideshow by Sean Horkheimer.
Drugs Used for Psychoses Chapter 18 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
General Instructions for CRF 3 Rev H To be completed at each follow up visit Patient Identification and Group Date of Visit Assessment performed physician.
Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) SAR/SUSAR Mette Krag Dept. of Intensive Care 4131 Copenhagen University Hospital Rigshospitalet,
Shock.
Overview of Influenza New York City Department of Health and Mental Hygiene.
Facility ID:Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M*Date of Birth: Ethnicity (specify):Race.
C-1 Safety Results S. aureus Bacteremia and Endocarditis Study Gloria Vigliani, M.D. Vice President, Medical Strategy Cubist Pharmaceuticals.
* QUINIDINE  Quinidine has pronounced cardiac anti muscarinic effects. It is absorbed orally. It undergoes extensive metabolism by the hepatic cytochrome.
*Facility ID # : __________*Event # : __________ *Patient ID # : _____________ Social Security # : ___ ___ ___ - ___ ___ - ___ ___ ___ ___ Secondary ID.
*Facility ID:*Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M*Date of Birth: Ethnicity (specify):Race.
1 BSO Welcome. 2 General Login Attestation 3 BSO Login.
Warning Signs Y es No Unk Persistent Vomiting…………..... Abdominal pain/Tenderness.. Mucosal Bleeding …………….. Lethargy, restlessness……….… Liver Enlargement.
* required for saving Tracking #: Facility ID:*Survey Year: Facility Characteristics *Ownership (check one): □ For profit □ Not for profit, including church.
*Facility ID # : _____________ *HCW ID # : _____________ Social Security # : ___ ___ ___ - ___ ___ - ___ ___ ___ ___ Secondary ID # : _____________ HCW.
Purposes of NHSN Participation in the NHSN reflects the individual facility’s need for high quality and timely data on adverse events and adherence to.
National Hospital Care Survey (NHCS). 2 Overview What is the National Center for Health Statistics (NCHS)? What is the National Hospital Care Survey (NHCS)?
[Presentation location] [Presentation date] (Confirm ABT logo) Building Bridges and Bonds (B3): An introduction.
A.Facility Information: Facility ID: __________ 1.Ownership of your dialysis center (choose one): ____For profit ____Not for profit ____Government 2. Location.
The Alien Flight Student Program AFSP An overview of the applications that encompass the AFSP Program COPYRIGHT AND GOVERNMENT PURPOSE RIGHTS NOTICE Copyright.
Evidence-Based Practice Working Group Focus Group Guide NCCCP Experiences with Using/Implementing the Template for Community Outreach (TCO) Brenda Adjei,
Correlation of National Influenza Surveillance Data to the Local Experience Kate Goodin, MPH Florida Department of Health Bureau of Epidemiology 6 th Annual.
Assurance of Confidentiality: The information obtained in this surveillance system that would permit identification of any individual or institution is.
National Hospital Care Survey (NHCS) Acute Coronary Syndrome Study.
Thank you very much for including the HD*Calc software ( on your website or social media platform. The National Cancer Institute.
*Facility ID:*Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M Other *Date of Birth: Ethnicity (specify):Race.
Facility ID:Procedure #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M*Date of Birth: Ethnicity (specify):Race.
Brady Act Requirements In November 1993, the Brady Handgun Violence Prevention Act of 1993 (Brady Act), Public Law , was signed into law requiring.
OMB Control No , Expires on: 11/30/2014.
DENGUE CASE INVESTIGATION REPORT CDC Dengue Branch and Puerto Rico Department of Health 1324 Calle Cañada, San Juan, P. R Tel. (787) ,
Facility Information: *Facility Name: __________________________________________________________________ *Main Telephone Number: ( ) ______-____________.
Søren Marker Jensen, MD, coordinating investigator
Acetylcysteine for Acetaminophen Poisoning
Psychiatric Treatment
NAP6 Perioperative Anaphylaxis
Toxicities and clinical issues with Immunotherapies
Plan of Correction CNA NCU 2014
Vascular reactions in children
CSPR Part II: Data Quality and the MEP Data Check Sheet
Patient Care Radiation Exposure and Contrast Media Considerations
Chemistry: Reactions in medicine
Chaper 20 Adrenoceptor Antagonists
University of Washington
Presentation transcript:

Facility ID#: Med Admin#: Healthcare Worker Demographics *HCW ID#: *HCW Name, Last:First:Middle: *Gender:  F  M  Other *Date of Birth:// *Work Location:*Occupation: Clinical Specialty: Information about the Antiviral Medication Infectious agent: Influenza*For season:____________________ (specify years) Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). Public reporting burden of this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333, ATTN: PRA ( ). CDC (Front), v6.4 Healthcare Worker Prophylaxis/Treatment Influenza Page 1 of 4 * Required *Indication (select one) *#*#Influenza subtype *Antiviral medication (Enter code from below) *Start dateStop date *Adverse reactions?  Prophylaxis  Treatment  Seasonal  Non-seasonal  Unknown ___ / ___ / ____ mm dd yyyy  Yes  No  Don’t know  Prophylaxis  Treatment  Seasonal  Non-seasonal  Unknown ___ / ___ / ____ mm dd yyyy  Yes  No  Don’t know  Prophylaxis  Treatment  Seasonal  Non-seasonal  Unknown ___ / ___ / ____ mm dd yyyy  Yes  No  Don’t know  Prophylaxis  Treatment  Seasonal  Non-seasonal  Unknown ___ / ___ / ____ mm dd yyyy  Yes  No  Don’t know  Prophylaxis  Treatment  Seasonal  Non-seasonal  Unknown ___ / ___ / ____ mm dd yyyy  Yes  No  Don’t know  Prophylaxis  Treatment  Seasonal  Non-seasonal  Unknown ___ / ___ / ____ mm dd yyyy  Yes  No  Don’t know  Prophylaxis  Treatment  Seasonal  Non-seasonal  Unknown ___ / ___ / ____ mm dd yyyy  Yes  No  Don’t know  Prophylaxis  Treatment  Seasonal  Non-seasonal  Unknown ___ / ___ / ____ mm dd yyyy  Yes  No  Don’t know  Prophylaxis  Treatment  Seasonal  Non-seasonal  Unknown ___ / ___ / ____ mm dd yyyy  Yes  No  Don’t know  Prophylaxis  Treatment  Seasonal  Non-seasonal  Unknown ___ / ___ / ____ mm dd yyyy  Yes  No  Don’t know Antiviral medications AMAN–amantadine (Symmetrel®) RIMAN–rimantadine(Flumadine®) ZANAM–zanamivir (Relenza®) OSELT–oseltamivir (Tamiflu®) OMB No Exp. Date: xx-xx-xxxx

Information about the Antiviral Medication (cont.) Adverse reactions to antiviral medication #1: (check all that apply)  Acute respiratory failure  Anaphylactic reaction  Arrhythmia  Behavior disturbances  Bronchospasm  Cardiac arrest  Cardiac failure  Coma  Convulsions; seizure  Delirium, delusions, stupor  Erythema multiforme  Hemorrhagic colitis  Hepatitis  Hypotension; orthostatic hypotension  Leukopenia; neutropenia  Life threatening overdose  Liver function test elevation  Mydriasis (in patients with untreated angle closure glaucoma  Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction  Oropharyngeal edema  Psychosis  Pulmonary edema  Serious skin rash  Suicide or self-harm attempt  Swelling of face or tongue  Syncope  Tachycardia  Toxic epidermal necrolysis/Stevens Johnson Syndrome  Urinary retention  Other ______________ Adverse reactions to antiviral medication #2: (check all that apply)  Acute respiratory failure  Anaphylactic reaction  Arrhythmia  Behavior disturbances  Bronchospasm  Cardiac arrest  Cardiac failure  Coma  Convulsions; seizure  Delirium, delusions, stupor  Erythema multiforme  Hemorrhagic colitis  Hepatitis  Hypotension; orthostatic hypotension  Leukopenia; neutropenia  Life threatening overdose  Liver function test elevation  Mydriasis (in patients with untreated angle closure glaucoma  Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction  Oropharyngeal edema  Psychosis  Pulmonary edema  Serious skin rash  Suicide or self-harm attempt  Swelling of face or tongue  Syncope  Tachycardia  Toxic epidermal necrolysis/Stevens Johnson Syndrome  Urinary retention  Other ______________ Adverse reactions to antiviral medication #3: (check all that apply)  Acute respiratory failure  Anaphylactic reaction  Arrhythmia  Behavior disturbances  Bronchospasm  Cardiac arrest  Cardiac failure  Coma  Convulsions; seizure  Delirium, delusions, stupor  Erythema multiforme  Hemorrhagic colitis  Hepatitis  Hypotension; orthostatic hypotension  Leukopenia; neutropenia  Life threatening overdose  Liver function test elevation  Mydriasis (in patients with untreated angle closure glaucoma  Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction  Oropharyngeal edema  Psychosis  Pulmonary edema  Serious skin rash  Suicide or self-harm attempt  Swelling of face or tongue  Syncope  Tachycardia  Toxic epidermal necrolysis/Stevens Johnson Syndrome  Urinary retention  Other ______________ Adverse reactions to antiviral medication #4: (check all that apply)  Acute respiratory failure  Anaphylactic reaction  Arrhythmia  Behavior disturbances  Bronchospasm  Cardiac arrest  Cardiac failure  Coma  Convulsions; seizure  Delirium, delusions, stupor  Erythema multiforme  Hemorrhagic colitis  Hepatitis  Hypotension; orthostatic hypotension  Leukopenia; neutropenia  Life threatening overdose  Liver function test elevation  Mydriasis (in patients with untreated angle closure glaucoma  Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction  Oropharyngeal edema  Psychosis  Pulmonary edema  Serious skin rash  Suicide or self-harm attempt  Swelling of face or tongue  Syncope  Tachycardia  Toxic epidermal necrolysis/Stevens Johnson Syndrome  Urinary retention  Other ______________ CDC (Back), v6.4 Page 2 of 4 Healthcare Worker Influenza Antiviral Medication Administration OMB No Exp. Date: xx-xx-xxxx

Information about the Antiviral Medication (cont.) Adverse reactions to antiviral medication #5: (check all that apply)  Acute respiratory failure  Anaphylactic reaction  Arrhythmia  Behavior disturbances  Bronchospasm  Cardiac arrest  Cardiac failure  Coma  Convulsions; seizure  Delirium, delusions, stupor  Erythema multiforme  Hemorrhagic colitis  Hepatitis  Hypotension; orthostatic hypotension  Leukopenia; neutropenia  Life threatening overdose  Liver function test elevation  Mydriasis (in patients with untreated angle closure glaucoma  Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction  Oropharyngeal edema  Psychosis  Pulmonary edema  Serious skin rash  Suicide or self-harm attempt  Swelling of face or tongue  Syncope  Tachycardia  Toxic epidermal necrolysis/Stevens Johnson Syndrome  Urinary retention  Other ______________ Adverse reactions to antiviral medication #6: (check all that apply)  Acute respiratory failure  Anaphylactic reaction  Arrhythmia  Behavior disturbances  Bronchospasm  Cardiac arrest  Cardiac failure  Coma  Convulsions; seizure  Delirium, delusions, stupor  Erythema multiforme  Hemorrhagic colitis  Hepatitis  Hypotension; orthostatic hypotension  Leukopenia; neutropenia  Life threatening overdose  Liver function test elevation  Mydriasis (in patients with untreated angle closure glaucoma  Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction  Oropharyngeal edema  Psychosis  Pulmonary edema  Serious skin rash  Suicide or self-harm attempt  Swelling of face or tongue  Syncope  Tachycardia  Toxic epidermal necrolysis/Stevens Johnson Syndrome  Urinary retention  Other ______________ Adverse reactions to antiviral medication #7: (check all that apply)  Acute respiratory failure  Anaphylactic reaction  Arrhythmia  Behavior disturbances  Bronchospasm  Cardiac arrest  Cardiac failure  Coma  Convulsions; seizure  Delirium, delusions, stupor  Erythema multiforme  Hemorrhagic colitis  Hepatitis  Hypotension; orthostatic hypotension  Leukopenia; neutropenia  Life threatening overdose  Liver function test elevation  Mydriasis (in patients with untreated angle closure glaucoma  Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction  Oropharyngeal edema  Psychosis  Pulmonary edema  Serious skin rash  Suicide or self-harm attempt  Swelling of face or tongue  Syncope  Tachycardia  Toxic epidermal necrolysis/Stevens Johnson Syndrome  Urinary retention  Other ______________ Adverse reactions to antiviral medication #8: (check all that apply)  Acute respiratory failure  Anaphylactic reaction  Arrhythmia  Behavior disturbances  Bronchospasm  Cardiac arrest  Cardiac failure  Coma  Convulsions; seizure  Delirium, delusions, stupor  Erythema multiforme  Hemorrhagic colitis  Hepatitis  Hypotension; orthostatic hypotension  Leukopenia; neutropenia  Life threatening overdose  Liver function test elevation  Mydriasis (in patients with untreated angle closure glaucoma  Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction  Oropharyngeal edema  Psychosis  Pulmonary edema  Serious skin rash  Suicide or self-harm attempt  Swelling of face or tongue  Syncope  Tachycardia  Toxic epidermal necrolysis/Stevens Johnson Syndrome  Urinary retention  Other ______________ CDC (Back), v6.4 Page 3 of 4 Healthcare Worker Influenza Antiviral Medication Administration OMB No Exp. Date: xx-xx-xxxx

Information about the Antiviral Medication (cont.) Adverse reactions to antiviral medication #9: (check all that apply)  Acute respiratory failure  Anaphylactic reaction  Arrhythmia  Behavior disturbances  Bronchospasm  Cardiac arrest  Cardiac failure  Coma  Convulsions; seizure  Delirium, delusions, stupor  Erythema multiforme  Hemorrhagic colitis  Hepatitis  Hypotension; orthostatic hypotension  Leukopenia; neutropenia  Life threatening overdose  Liver function test elevation  Mydriasis (in patients with untreated angle closure glaucoma  Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction  Oropharyngeal edema  Psychosis  Pulmonary edema  Serious skin rash  Suicide or self-harm attempt  Swelling of face or tongue  Syncope  Tachycardia  Toxic epidermal necrolysis/Stevens Johnson Syndrome  Urinary retention  Other ______________ Adverse reactions to antiviral medication #10: (check all that apply)  Acute respiratory failure  Anaphylactic reaction  Arrhythmia  Behavior disturbances  Bronchospasm  Cardiac arrest  Cardiac failure  Coma  Convulsions; seizure  Delirium, delusions, stupor  Erythema multiforme  Hemorrhagic colitis  Hepatitis  Hypotension; orthostatic hypotension  Leukopenia; neutropenia  Life threatening overdose  Liver function test elevation  Mydriasis (in patients with untreated angle closure glaucoma  Neuroleptic malignant syndrome with abrupt discontinuation or dose reduction  Oropharyngeal edema  Psychosis  Pulmonary edema  Serious skin rash  Suicide or self-harm attempt  Swelling of face or tongue  Syncope  Tachycardia  Toxic epidermal necrolysis/Stevens Johnson Syndrome  Urinary retention  Other ______________ Custom Fields Label ________________________ ___/___/___ ________________________ ___________ Label ________________________ ___/___/___ ________________________ ___________ Comments CDC (Back), v6.4 Page 4 of 4 Healthcare Worker Influenza Antiviral Medication Administration OMB No Exp. Date: xx-xx-xxxx